Eli Lilly’s weekly insulin intensifies race with Novo Nordisk

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company’s race with Novo Nordisk to develop longer-acting insulins.

Previous post Conservative cable TV brand Newsmax plans to go public
Next post Family offices are about to surpass hedge funds, with $5.4 trillion in assets by 2030